<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080261</url>
  </required_header>
  <id_info>
    <org_study_id>S2069</org_study_id>
    <nct_id>NCT01080261</nct_id>
  </id_info>
  <brief_title>PROMUS Element Japan Small Vessel Trial</brief_title>
  <official_title>A Prospective Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of a Small Vessel De Novo Coronary Artery Lesion in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-randomized, small vessel (SV) trial at approximately 15 sites in Japan to enroll 60
      patients with a de novo lesion ≤28 mm in length (by visual estimate) in a native coronary
      artery ≥2.25 mm to &lt;2.50 mm in diameter (by visual estimate). Approximately thirty patients
      will be randomly assigned to the angiographic subset to also undergo angiographic assessment
      after the 12-month clinical follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>A major adverse cardiac event (MACE) is defined as any ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI, Q-wave and non-Q-wave), or cardiac death. Reported as percentage of participants who have experienced a MACE event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase- myoglobin band (CK-MB) or troponin above upper limit of normal (ULN) (baseline troponin &lt;ULN); if no new Q-waves total CK or troponin &gt;3× ULN (baseline troponin &lt;ULN) plus at least one of the following: electrocardiogram changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5× ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Death (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Participants who died from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded. Reported as percentage of participants who experienced cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.Reported as percentage of participants who experienced a TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. Reported as percentage of participants who experienced a TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF) (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Includes any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF. Reported as percentage of participants who experienced a TVF event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF) (Percentage of Participants With an Event)</measure>
    <time_frame>9 months</time_frame>
    <description>Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel. Reported as percentage of participants who experienced a TLF event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</measure>
    <time_frame>0-30 Days (Early)</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</measure>
    <time_frame>&gt;30 days - 9 months</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success (Percentage of Stents)</measure>
    <time_frame>At time of index procedure</time_frame>
    <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedural Success (Percentage of Participants)</measure>
    <time_frame>While participant is in the hospital</time_frame>
    <description>Expressed as percentage of participants in whom mean lesion diameter stenosis was &lt;30% with TIMI 3 flow (visually assessed) and who did not experience an occurrence of in-hospital myocardial infarction, target vessel revascularization, or cardiac death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PROMUS Element</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus-eluting coronary stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROMUS Element</intervention_name>
    <description>PROMUS Element Everolimus-Eluting Coronary Stent System</description>
    <arm_group_label>PROMUS Element</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 20 years of age

          -  Patient understands the study requirements and the treatment procedures and provides
             written informed consent before any study-specific tests or procedures are performed

          -  Patient is eligible for percutaneous coronary intervention (PCI) with regards to the
             target lesion Patient is considered suitable for PCI if any of the following criteria
             meet.

          -  Evidence of ischemia documented with stress electrocardiogram (ECG) and/or any
             diagnostic imaging tests.

          -  Target vessel supplies blood to relatively large area of the myocardium.

          -  Target lesion is a possible culprit of angina.

          -  Target vessel is a potential collateral source for other major vessels

          -  Patient has documented stable angina pectoris or documented silent ischemia; or
             unstable angina pectoris

          -  Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

          -  Patient has a left ventricular ejection fraction (LVEF) ≥30% as measured within 30
             days prior to enrollment

          -  Patient is willing to comply with all protocol-required follow-up evaluation

        Exclusion Criteria:

          -  Patient has clinical symptoms and/or ECG changes consistent with acute myocardial
             infarction (MI)

          -  Patient has had a known diagnosis of recent MI (i.e., within 72 hours prior to the
             index procedure) and has elevated enzymes at the time of the index procedure as
             follows.

               -  Patients are excluded if any of the following criteria are met at the time of the
                  index procedure.

               -  If creatine kinase-myoglobin band (CK-MB) is &gt;2× upper limit of normal (ULN), the
                  patient is excluded regardless of the CK Total.

               -  If CK MB is 1 2× ULN, the patient is excluded if the CK Total is &gt;2× ULN.

               -  If CK Total/CK MB are not used and Troponin is, patients are excluded if the
                  following criterion is met at the time of the index procedure.

               -  Troponin &gt;1× ULN with at least one of the following.

               -  Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia
                  (e.g., &gt;1 mm ST segment elevation or depression in consecutive leads or new left
                  bundle branch block [LBBB]);

               -  Development of pathological Q waves in the ECG; or

               -  Imaging evidence of new loss of viable myocardium or new regional wall motion
                  abnormality.

        Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK
        MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling the
        patient.

          -  Patient has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or
             after the index procedure

          -  Patient is receiving oral or intravenous immunosuppressive therapy (inhaled steroids
             are not excluded) or has known life-limiting immunosuppressive or autoimmune disease
             (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including
             diabetes mellitus)

          -  Patient is receiving chronic (≥72 hours) anticoagulation therapy (e.g., heparin,
             warfarin) for indications other than acute coronary syndrome

          -  Patient has a platelet count &lt;100,000 cells/mm^3 or &gt;700,000 cells/mm^3

          -  Patient has a white blood cell (WBC) count &lt;3,000 cells/mm^3

          -  Patient has documented or suspected liver disease, including laboratory evidence of
             hepatitis

          -  Patient is on dialysis or has known renal insufficiency (i.e., Creatinine &gt; 2.0 mg/dl
             or &gt;150 μmol/L)

          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within the past 6 months, or has any permanent neurologic defect that may cause
             non-compliance with the protocol

          -  Target vessel or side branch has been treated with any type of PCI (e.g., balloon
             angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index
             procedure (excluding PCI of the non-target lesion within the target vessel treated
             during the index procedure (Refer to Multiple Interventions During Index Procedure))

          -  Target vessel has been treated within 10 mm proximal or distal to the target lesion
             (by visual estimate) with any type of PCI (e.g., balloon angioplasty, stent, cutting
             balloon, atherectomy) at any time prior to the index procedure

          -  Non-target vessel or side branch has been treated with any type of PCI (e.g., balloon
             angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index
             procedure

          -  Planned or actual target vessel treatment with an unapproved device, directional or
             rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
             catheter immediately prior to stent placement

          -  Planned PCI or CABG after the index procedure

          -  Patient previously treated at any time with coronary intravascular brachytherapy

          -  Patient has a known allergy to the study stent system or protocol-required concomitant
             medications (e.g., stainless steel, platinum, chromium, nickel, tungsten, acrylic,
             fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be
             adequately premedicated

          -  Patient has an active peptic ulcer or active gastrointestinal (GI) bleeding

          -  Patient has one of the following.

               -  Other serious medical illness (e.g., cancer, congestive heart failure) that may
                  reduce life expectancy to less than 24 months

               -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

               -  Planned procedure that may cause non-compliance with the protocol or confound
                  data interpretation

          -  Patient is participating in another investigational drug or device clinical trial that
             has not reached its primary endpoint

          -  Patient intends to participate in another investigational drug or device clinical
             trial within 12 months after the index procedure

          -  Patient with known intention to procreate within 12 months after the index procedure
             (Women of child-bearing potential who are sexually active must agree to use a reliable
             method of contraception from the time of screening through 12 months after the index
             procedure.)

          -  Patient is a woman who is pregnant or nursing (A pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential.)

          -  Patient has more than 1 target lesion and 1 non-target lesion, which will be treated
             during the index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoshi General Hospital</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakodate Municipal Hospital</name>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Social Insurance Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Labour Health and Welfare Organization Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-City Eastern Hospital</name>
      <address>
        <city>Yokohama City</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Labour Health and Welfare Organization Kumamoto Rosai Hospital</name>
      <address>
        <city>Yatsushiro-shi</city>
        <state>Kumamoto-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo-to</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo-to</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo-tu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <results_first_submitted>March 19, 2012</results_first_submitted>
  <results_first_submitted_qc>March 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2012</results_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of 60 patients was planned and 60 patients were enrolled at 14 sites in Japan from February 8, 2010 to June 15, 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PROMUS Element</title>
          <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PROMUS Element</title>
          <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.20" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group. Not all participants have one of these comorbidity measures.</description>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Renal Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Gastrointestinal Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous Percutaneous Coronary Intervention (PCI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Coronary Artery Bypass Graft (CABG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Myocardial Infarction (MI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Silent Ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History: Left Ventricular Ejection Fraction</title>
          <description>Left ventricular ejection fraction (LVEF) is an assessment of the amount of blood emptied from the left ventricle during systolic contraction, which is indicative of global ventricular function.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.27" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factors</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smoking, Ever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Treated Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family History of Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Target Lesion Vessel</title>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Left Anterior Descending Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Lesion Location</title>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ostial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Reference Vessel Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.02" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.56" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.91" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Percent Diameter Stenosis</title>
          <description>Extent of stenosis of the target lesion (measured as percent of area stenosed)</description>
          <units>percent stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.52" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group. Not all participants have one of these lesion characteristics.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eccentric Lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 45 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 90 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tortuosity, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcification, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bifurcation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: American College of Cardiology (ACC)/American Heart Association (AHA) Class</title>
          <description>Type A:minimally complex, readily accessible, non angulated, smooth contour, little to no calcification, less than totally occlusive, not ostial in location, no major side branch involvement, absence of thrombus.
Type B:moderately complex, eccentric, moderate tortuosity and angulation, moderate or heavy calcification, total occlusion &lt; 3 months old, ostial in location, presence of thrombus; type B1 has one adverse characteristic and B2 has ≥2. Type C:severely complex, diffuse, excessive tortuosity and angulation, total occlusions &gt; 3 months old, degenerated vein grafts and friable lesions.</description>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic - Pre-Procedure Thrombolysis In Myocardial Infarction (TIMI) Flow</title>
          <description>TIMI 0 - No perfusion; TIMI 1 - Penetration with minimal perfusion; TIMI 2 - Partial perfusion; TIMI 3 - Complete perfusion</description>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TIMI 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Events (MACE) (Percentage of Participants With an Event)</title>
        <description>A major adverse cardiac event (MACE) is defined as any ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI, Q-wave and non-Q-wave), or cardiac death. Reported as percentage of participants who have experienced a MACE event.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE) (Percentage of Participants With an Event)</title>
          <description>A major adverse cardiac event (MACE) is defined as any ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI, Q-wave and non-Q-wave), or cardiac death. Reported as percentage of participants who have experienced a MACE event.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A one-group exact binomial test was used to test the hypothesis that the percentage of patients experiencing a MACE event (primary endpoint) in the PROMUS Element cohort is less than the predefined performance goal of 24.1% (based on historical outcomes with plain balloon angioplasty [20.2%] plus an adjustment of 3.9% for small vessels).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Study had 91% statistical power to demonstrate that the 9-month rate for MACE (accounting for an expected 9-month attrition rate of 10%) is less than the performance goal, assuming a 9-month MACE rate of 8.2%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>One-group exact binomial test</method>
            <param_type>Percent of patients experiencing a MACE</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (Percentage of Participants With an Event)</title>
        <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase- myoglobin band (CK-MB) or troponin above upper limit of normal (ULN) (baseline troponin &lt;ULN); if no new Q-waves total CK or troponin &gt;3× ULN (baseline troponin &lt;ULN) plus at least one of the following: electrocardiogram changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5× ULN</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) (Percentage of Participants With an Event)</title>
          <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase- myoglobin band (CK-MB) or troponin above upper limit of normal (ULN) (baseline troponin &lt;ULN); if no new Q-waves total CK or troponin &gt;3× ULN (baseline troponin &lt;ULN) plus at least one of the following: electrocardiogram changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5× ULN</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Death (Percentage of Participants With an Event)</title>
        <description>Participants who died from any cause</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Death (Percentage of Participants With an Event)</title>
          <description>Participants who died from any cause</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death (Percentage of Participants With an Event)</title>
        <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded. Reported as percentage of participants who experienced cardiac death.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death (Percentage of Participants With an Event)</title>
          <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded. Reported as percentage of participants who experienced cardiac death.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (Percentage of Participants With an Event)</title>
        <description>Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.Reported as percentage of participants who experienced a TVR.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (Percentage of Participants With an Event)</title>
          <description>Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.Reported as percentage of participants who experienced a TVR.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (Percentage of Participants With an Event)</title>
        <description>Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. Reported as percentage of participants who experienced a TLR.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all participants underwent clinical follow-up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (Percentage of Participants With an Event)</title>
          <description>Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. Reported as percentage of participants who experienced a TLR.</description>
          <population>Analysis was intention to treat; all participants underwent clinical follow-up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF) (Percentage of Participants With an Event)</title>
        <description>Includes any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF. Reported as percentage of participants who experienced a TVF event.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF) (Percentage of Participants With an Event)</title>
          <description>Includes any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF. Reported as percentage of participants who experienced a TVF event.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF) (Percentage of Participants With an Event)</title>
        <description>Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel. Reported as percentage of participants who experienced a TLF event.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF) (Percentage of Participants With an Event)</title>
          <description>Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel. Reported as percentage of participants who experienced a TLF event.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
        <time_frame>0-30 Days (Early)</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
        <time_frame>&gt;30 days - 9 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event)</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success (Percentage of Stents)</title>
        <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
        <time_frame>At time of index procedure</time_frame>
        <population>Analysis was intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success (Percentage of Stents)</title>
          <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
          <population>Analysis was intention to treat</population>
          <units>percentage of stents</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Stents Implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Procedural Success (Percentage of Participants)</title>
        <description>Expressed as percentage of participants in whom mean lesion diameter stenosis was &lt;30% with TIMI 3 flow (visually assessed) and who did not experience an occurrence of in-hospital myocardial infarction, target vessel revascularization, or cardiac death.</description>
        <time_frame>While participant is in the hospital</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Procedural Success (Percentage of Participants)</title>
          <description>Expressed as percentage of participants in whom mean lesion diameter stenosis was &lt;30% with TIMI 3 flow (visually assessed) and who did not experience an occurrence of in-hospital myocardial infarction, target vessel revascularization, or cardiac death.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PROMUS Element</title>
          <description>Participants enrolled to receive a PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In Japan, the study agreement was executed between the head of hospital (not PI) and Boston Scientific Japan. The site must get written approval before they publish any study data/information to an outside community such as a scientific society.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruth Starzyk, Ph.D.</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>508-683-6577</phone>
      <email>ruth.starzyk@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

